logo-loader
viewOncimmune

Oncimmune Hldngs PLC - Grant of Options and PDMR notification

RNS Number : 4420P
Oncimmune Holdings PLC
09 June 2020
 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Grant of Options and PDMR notification

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that, as part of its annual management incentivisation scheme, options ("Options") to subscribe for an aggregate of 324,474 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 5 June 2020 to each of Adam Hill, Chief Executive Officer, Matthew Hall, Chief Financial Officer, Matthew Luttrell, Chief Commercial Officer, and Tariq Sethi, Chief Scientific Officer as follows:

 

Name

Position

Number of Share Options Awarded

Exercise Price per Ordinary

Share

Total Options held post grant

Total number of Ordinary Shares currently held

% of total issued share capital

Adam Hill

Chief Executive Officer

129,288

£1.195

526,113

40,913

0.06%

Matthew Hall

Chief Financial Officer

134,936

£1.195

295,486

11,935

0.02%

Matthew Luttrell

Chief Commercial Officer

42,677

£1.195

266,361

-

-

Tariq Sethi

Chief Scientific Officer

17,573

£1.195

109,678

-

-

 

The Options have been granted under the 2016 Share Option Plan, have an exercise price of £1.195, being the closing price of Ordinary Shares on  4 June 2020, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.  

 

This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

1)   Adam Hill

2)   Matthew Hall

3)   Matthew Luttrell

4)   Tariq Sethi

2

 

Reason for the notification

 

a)

 

Position/status

 

 

1)   Chief Executive Officer

2)   Chief Financial Officer

3)   Chief Commercial Officer

4)   Chief Scientific Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Oncimmune Holdings plc

b)

 

LEI

 

 

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




1) £1.195

129,288




2) £1.195

134,936




3) £1.195

42,677




4) £1.195

17,573







d)

 

Aggregated information




- Aggregated volume

As above     



- Price




e)

 

Date of the transaction

 

 

5 June 2020

f)

 

Place of the transaction

 

 

Outside a trading venue

 

For further information:

Oncimmune Holdings plc

Ron Kirschner, General Counsel & Company Secretary

[email protected]

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUPUGAQUPUGCB

Quick facts: Oncimmune

Price: 139.5

Market: AIM
Market Cap: £88.6 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20